ReviewExpert review of clinical pharmacology2013
The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations.
Review in Expert review of clinical pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap.Drug design, development and therapy · 2018Pooled it
- Clinical characteristics of the asthma-COPD overlap syndrome--a systematic review.International journal of chronic obstructive pulmonary disease · 2015Pooled it
- Differential DAMP release was observed in the sputum of COPD, asthma and asthma-COPD overlap (ACO) patients.Scientific reports · 2019Trial
- Reassessing the risk-modifying effects of novel antidiabetic agents on asthma-COPD overlap syndrome: a dose-stratified network meta-analysis of 316,832 adults from 128 randomised trials.EClinicalMedicine · 2026Article
- Article
- Asthma and chronic obstructive disease overlap (ACO), a systematic review of prevalence and co-morbidity factors based on diagnostic criteria.Journal of pharmaceutical policy and practice · 2026Review
- New insights on pharmacological potential of montelukast: a comprehensive review.Inflammopharmacology · 2025Review
- Association of eosinophil-to-monocyte ratio with asthma exacerbations in adults: a cross-sectional analysis of NHANES data.BMC pulmonary medicine · 2025Article
- Assessment of functional diversities in patients with Asthma, COPD, Asthma-COPD overlap, and Cystic Fibrosis (CF).PloS one · 2024Article
- Review
- Article
- Pharmacological Strategies and Recent Advancement in Nano-Drug Delivery for Targeting Asthma.Life (Basel, Switzerland) · 2022Review
- Functional Predictors Discriminating Asthma-COPD Overlap (ACO) from Chronic Obstructive Pulmonary Disease (COPD).International journal of chronic obstructive pulmonary disease · 2022Article
- ACO (Asthma-COPD Overlap) Is Independent from COPD, a Case in Favor: A Systematic Review.Diagnostics (Basel, Switzerland) · 2021Review
- Post-anesthesia care unit desaturation in adult deep extubation patients.BMC research notes · 2021Article
- Integrating Comorbidities and Phenotype-Based Medicine in Patient-Centered Medicine in COPD.Journal of clinical medicine · 2020Review
- A comparison of diagnostic consistency for asthma-chronic obstructive pulmonary disease overlap and clinical characteristics study.BMC pulmonary medicine · 2019Article
- Clinical Characteristics Of Patients With Asthma COPD Overlap (ACO) In Australian Primary Care.International journal of chronic obstructive pulmonary disease · 2019Article
- Increased Risk of Exacerbation in Asthma Predominant Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome.Tuberculosis and respiratory diseases · 2018Article
- Effect of Liuweibuqi capsules on CD4Journal of thoracic disease · 2018Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is a commonly encountered yet loosely defined clinical entity. ACOS accounts for approximately 15-25% of the obstructive airway diseases and patients experience worse outcomes compared with asthma or COPD alone. Patients with ACOS have the combined risk factors of smoking and atopy, are generally younger than patients with COPD and experience acute exacerbations with higher frequency and greater severity than lone COPD. Pharmacotherapeutic considerations require an integrated approach, first to identify the relevant clinical phenotype(s), then to determine the best available therapy. The authors discuss the array of existing and emerging classes of drugs that could benefit those with ACOS and share their therapeutic approach. A consensus international definition of ACOS is needed to design prospective, randomized clinical trials to evaluate specific drug interventions on important outcomes such as lung function, acute exacerbations, quality of life and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.